Clobetasol propionate - Where, when, why?

Drugs of Today

Volumn 44, Issue 7, 2008, Pages 547-557

  Pels, Ragna ^a   Sterry, Wolfram ^b   Lademann, Jürgen ^b  

^a Polikum Friedenau ^*  (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL PROPIONATE; CORTICOSTEROID; HYDROCORTISONE; NYSTATIN; SHAMPOO; TRIAMCINOLONE ACETONIDE;

ALOPECIA AREATA; ATOPIC DERMATITIS; BULLOUS PEMPHIGOID; BURN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CUSHING SYNDROME; DISCOID LUPUS ERYTHEMATOSUS; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; ECZEMA; GLAUCOMA; HIRSUTISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOPIGMENTATION; LICHEN PLANUS; LICHEN SCLEROSUS ET ATROPHICUS; LOTION; MOUTH ULCER; PRURITUS; PSORIASIS; REVIEW; SIDE EFFECT; SKIN ALLERGY; SKIN ATROPHY; SKIN DISEASE; THRUSH;

ADMINISTRATION, CUTANEOUS; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; CLOBETASOL; DERMATITIS, ATOPIC; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PSORIASIS; VULVAR LICHEN SCLEROSUS;

EID: 51349086438     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.7.1122221     Document Type: Review

References (81)

1. Sommer, A., Veraart, J., Neumann, M., Kessels, A. Evaluation of the vasoconstrictive effects of topical steroids by laser-Doppler-perfusion- imaging. Acta Derm Venereol 1998, 78(1): 15-8.
2. Sulzberger, M.B., Witten, V.H. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol 1952, 19(2): 101-2.
3. Hepburn, D.J. Aeling, J.L., Weston, W.L. A reappraisal of topical steroid potency. Pediatr Dermatol 1996, 13(3): 239-45.
4. Drake, L.A., Dinehart, S.M., Farmer, E.R. et al. Guidelines of care for the use of topical glucocorticosteroids. American Academy of Dermatology. J Am Acad Dermatol 1996, 35(4): 615-9.
5. Gilbertson, E.O., Spellman, M.C., Piacquadio, D.J., Mulford, M.I. Super potent topical corticosteroid use associated with adrenal suppression: Clinical considerations. J Am Acad Dermatol 1998, 38(2, Pt. 2): 318-21.
6. Gold-von Simson, G., Kohn, B., Axelrod, F.B. Cushing syndrome from topical foam steroid use in an adolescent male. Clin Pediatr (Phila) 2006, 45(1): 97-100.
7. Siklar, Z., Bostanci, I., Atli, O., Dallar, Y. An infantile Cushing syndrome due to misuse of topical steroid. Pediatr Dermatol 2004, 21(5): 561-3.
8. Staughton, R.C., August, P.J. Cushing's syndrome and pituitary - adrenal suppression due to clobetasol propionate. Br Med J 1975, 24;2(5968): 419-21.
9. Carruthers, J.A., August, P.J., Staughton, R.C. Observations on the systemic effect of topical clobetasol propionate (Dermovate). Br Med J 1975, 25; 4(5990): 203-4.
10. van Tuyl, S.A., Slee, P.H. Are the effects of local treatment with glucocorticoids only local? Neth J Med 2002, 60(3): 130-2.
11. Yang, S., Zhang, L. Glucocorticoids and vascular reactivity. Curr Vasc Pharmacol 2004, 2(1): 1-12.
12. McKenzie, A.W., Stoughton, R.B. Method for comparing percutaneous absorption of steroids. Arch Dermatol 1962, 86: 606-10.
13. Cornell, R.C., Stoughton, R.B. Correlation of the skin blanching assay and clinical activity in psoriasis. Arch Dermatol 1985, 121(1): 63-7.
14. Noon, J.P., Evans, C.E., Haynes, W.G., Webb, D.J., Walker, B.R. A comparison of techniques to assess skin blanching following the topical application of glucocorticoids. Br J Dermatol 1996, 134(5): 837-42.
15. Sommer, A., Lucassen, G.W., Houben, A.J., Neumann, M.H. Vasoconstrictive effect of topical applied corticosteroids measured by laser Doppler imaging and reflectance spectroscopy. Microvasc Res 2003, 65(3): 152-9.
16. Emtestam, L., Kuzmina, N., Talme, T. Evaluation of the effects of topical clobetasol propionate by visual score, electrical impedance and laser Doppler flowmetry. Skin Res Technol 2007, 13(1): 73-8.
17. Weigmann, H., Lademann, J., v Pelchrzim, R. et al. Bioavailability of clobetasol propionate-quantification of drug concentrations in the stratum corneum by dermatopharmacokinetics using tape stripping. Skin Pharmacol Appl Skin Physiol 1999, 12(1-2): 46-53.
18. Gordon, M.L. The role of clobetasol propionate emollient 0.05% in the treatment of patients with dry, scaly, corticosteroid-responsive dermatoses. Clin Ther 1998, 20(1): 26-39.
19. Jegasothy, B., Jacobson, C., Levine, N. at al. Clobetasol propionate versus fluocinonide creams in psoriasis and eczema. Int J Dermatol 1985, 24(7): 461-5.
20. Angelo, J.S., Kar, B.R., Thomas, J. Comparison of clinical efficacy of topical tazarotene 0.1% cream with topical clobetasol propionate 0.05% cream in chronic plaque psoriasis: A double-blind, randomized, right-left comparison study. Indian J Dermatol Venereol Leprol 2007, 73(1): 65.
21. Griffiths, C.E., Finlay, A.Y., Fleming, C.J., Barker, J.N., Mizzi, F., Arsonnaud, S. A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. J Dermatolog Treat 2006, 17(2): 90-5.
22. Hradil, E., Lindstrom, C., Moller, H. Intermittent treatment of psoriasis with clobetasol propionate. Acta Derm Venereol 1978, 58(4): 375-7.
23. Svartholm, H., Larsson, L., Frederiksen, B. Intermittent topical treatment of psoriasis with clobetasol propionate ("Dermovate"). Curr Med Res Opin 1982, 8(3): 154-7.
24. Lowe, N., Feldman, S.R., Sherer, D. et al. Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis. J Dermatolog Treat 2005, 16(3): 158-64.
25. Pearce, D.J., Stealey, K.H., Balkrishnan, R., Fleischer, A.B.Jr., Feldman, S.R. Psoriasis treatment in the United States at the end of the 20th century. Int J Dermatol 2006, 45(4): 370-4.
26. Volden, G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Derm Venereol 1992, 72(1): 69-71.
27. Maloney, J.M., Morman, M.R., Stewart, D.M., Tharp, M.D., Brown, J.J., Rajagopalan, R. Clobetasol propionate emollient 0.05% in the treatment of atopic dermatitis. Int J Dermatol 1998, 37(2): 142-4.
28. Ashworth, J., Booker, J., Breathnach, S.M. Effects of topical corticosteroid therapy on Langerhans cell antigen presenting function in human skin. Br J Dermatol 1988, 118(4): 457-69.
29. Paquet, P., Richelle, M., Lapiere, C.M. Bullous pemphigoid treated by topical corticosteroids. Acta Derm Venereol 1991, 71(6): 534-5.
30. Westerhof, W. Treatment of bullous pemphigoid with topical clobetasol propionate. J Am Acad Dermatol 1989, 20(3): 458-61.
31. Joly, P., Roujeau, J.C., Benichou, J. et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002, 346(5): 321-7.
32. Joly, P., Fontaine, J., Roujeau, J.C. The role of topical corticosteroids in bullous pemphigoid in the elderly. Drugs Aging 2005, 22(7): 571-6.
33. Lo Muzio, L., della Valle, A., Mignogna, M.D., Pannone, G., Bucci, P., Bucci, E., Sciubba, J. The treatment of oral aphthous ulceration or erosive lichen planus with topical clobetasol propionate in three preparations: A clinical and pilot study on 54 patients. J Oral Pathol Med 2001, 30(10): 611-7.
34. Goette, D.K. Resolution of necrobiosis lipoidica with exclusive clobetasol propionate treatment. J Am Acad Dermatol 1990, 22(5, Pt. 1): 855-6.
35. Lenane, P., Pope, E., Krafchik, B. Congenital alopecia areata. J Am Acad Dermatol 2005, 52(2, Suppl. 1): 8-11.
36. Tosti, A., Piraccini, B.M., Pazzaglia, M., Vincenzi, C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol 2003, 49(1): 96-8.
37. Ayhan, A., Guven, S., Guvendag Guven, E.S., Sakinci, M., Gultekin, M., Kucukali, T. Topical testosterone versus clobetasol for vulvar lichen sclerosus. Int J Gynaecol Obstet 2007, 96(2): 117-21.
38. Diakomanolis, E.S., Haidopoulos, D., Syndos, M., Rodolakis, A., Stefanidis, K., Chatzipapas, J., Michalas, S. Vulvar lichen sclerosus in postmenopausal women: A comparative study for treating advanced disease with clobetasol propionate 0.05%. Eur J Gynaecol Oncol 2002, 23(6): 519-22.
39. Renaud-Vilmer, C., Cavelier-Balloy, B., Porcher, R., Dubertret, L. Vulvar lichen sclerosus: Effect of long-term topical application of a potent steroid on the course of the disease. Arch Dermatol 2004, 140(6): 709-12.
40. Falkenstein, E., Tillmann, H.C., Christ, M., Feuring, M., Wehling, M. Multiple actions of steroid hormones - a focus on rapid, nongenomic effects. Pharmacol Rev 2000, 52(4): 513-56.
41. Serres, M., Viac, J., Schmitt, D. Glucocorticoid receptor localization in human epidermal cells. Arch Dermatol Res 1996, 288(3): 140-6.
42. Hoetzenecker, W., Meingassner, J.G., Ecker, R., Stingl, G., Stuetz, A., Elbe-Burger, A. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004, 122(3): 673-84.
43. Barnes, P.J. Anti-inflammatory actions of glucocorticoids: Molecular mechanisms. Clin Sci 1998, 94(6): 557-72.
44. Solito, E., Mulla, A., Morris, J.F., Christian, H.C., Flower, R.J., Buckingham, J.C. Dexamethasone induces rapid serine-phosphorylation and membrane translocation of annexin 1 in a human folliculostellate cell line via a novel nongenomic mechanism involving the glucocorticoid receptor, protein kinase C, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase. Endocrinology 2003, 144(4): 1164-74.
45. Croxtall, J.D., Choudhury, Q., Flower, R.J. Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br J Pharmacol 2000, 130(2): 289-98.
46. Naumann, L., Feist, E., Straub, R.H., Burmester, G.R., Buttgereit, F. Potencies of topical glucocorticoids to mediate genomic and nongenomic effects on human peripheral blood mononuclear cells. Biochem Pharmacol 2006, 71(4): 530-9.
47. + ions into concanavalin A-stimulated thymocytes. Biochem J 1997, 326(Pt 2): 329-32.
48. Kuhnke, A., Burmester, G.R., Krauss, S., Buttgereit, F. Bioenergetics of immune cells to assess rheumatic disease activity and efficacy of glucocorticoid treatment. Ann Rheum Dis 2003, 62(2): 133-9.
49. Schmid, D., Burmester, G.R., Tripmacher, R., Kuhnke, A., Buttgereit, F. Bioenergetics of human peripheral blood mononuclear cell metabolism in quiescent, activated, and glucocorticoid-treated states. Biosci Rep 2000, 20(4): 289-302.
50. Portner, M., Mollmann, H., Rohdewald, P. Glucocorticoid receptors in human synovial tissue and relative receptor affinities of glucocorticoid-21- esters. Pharm Res 1988, 5(10): 623-7.
51. Huang, X., Tanojo, H., Lenn, J., Deng, C.H., Krochmal, L. A novel foam vehicle for delivery of topical corticosteroids. J Am Acad Dermatol 2005, 53(1, Suppl. 1): 26-38.
52. Feldman, S.R., Housman, T.S. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol 2003, 4(4): 221-4.
53. Franz, T.J., Lehman, P.A., Feldman, S.R., Spellman, M.C. Bioavailability of clobetasol propionate in different vehicles. Skin Pharmacol Appl Skin Physiol 2003, 16(4): 212-6.
54. Gupta, A.K., Abramovits, W., Gover, M.D. Clobex (clobetasol propionate) Spray, 0.05%. Skinmed 2006, 5(4): 184-5.
55. Decroix, J., Pres, H., Tsankov, N., Poncet, M., Arsonnaud, S. Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis. Cutis 2004, 74(3): 201-6.
56. Breneman, D., Fleischer, A.B.Jr., Kaplan, D. et al. Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: A randomized evaluation versus clobetasol propionate emollient cream. J Drugs Dermatol 2005, 4(3): 330-6.
57. Lowe, N., Feldman, S.R., Sherer, D. et al. Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis. J Dermatolog Treat 2005, 16(3): 158-64.
58. Jarratt, M, Breneman, D., Gottlieb, A.B., Poulin, Y., Liu, Y., Foley, V. Clobetasol propionate shampoo 0.05%: A new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol 2004, 3(4): 367-73.
59. Andres, P., Poncet, M., Farzaneh, S., Soto P. Short-term safety assessment of clobetasol propionate 0.05% shampoo: Hypothalamic - pituitary - adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis. J Drugs Dermatol 2006, 5(4): 328-32.
60. Reygagne, P., Mrowietz, U., Decroix, J. et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: A randomized comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatolog Treat 2005, 16(1): 31-6.
61. Jarratt, M.T., Clark, S.D., Savin, R.C., Swinyer, L.J., Safley, C.F., Brodeil, R.T., Yu, K. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis. Cutis 2006, 78(5): 348-54.
62. Beutner, K., Chakrabarty, A., Lemke, S., Yu, K. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. J Drugs Dermatol 2006, 5(4): 357-60.
63. Franz, T.J., Parsell, D.A., Myers, J.A., Hannigan, J.F. Clobetasol propionate foam 0.05%: A novel vehicle with enhanced delivery. Int J Dermatol 2000, 39(7): 535-8.
64. Bergstrom, K.G., Arambula, K., Kimball, A.B. Medication formulation affects quality of life: A randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis 2003, 72(5): 407-11.
65. Gottlieb, A.B., Ford, R.O., Spellman, M.C. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg 2003, 7(3): 185-92.
66. Tosti, A., Iorizzo, M., Botta, G.L., Milani, M. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: A randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol 2006, 20(10): 1243-7.
67. Vena, G.A., Cassano, N., D'Argento, V., Milani, M. Clobetasol propionate 0.05% in a novel foam formulation is safe and effective in the short-term treatment of patients with delayed pressure urticaria: A randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006, 154(2): 353-6.
68. Melian, E.B., Spencer, C.M., Jarvis, B. Clobetasol propionate foam, 0.05%. Am J Clin Dermatol 2001, 2(2):89-92.
69. Reid, D.C., Kimball, A.B. Clobetasol propionate foam in the treatment of psoriasis. Expert Opin Pharmacother 2005, 6(10): 1735-40.
70. Warino, L., Balkrishnan, R., Feldman, S.R. Clobetasol propionate for psoriasis: Are ointments really more potent? J Drugs Dermatol 2006, 5(6): 527-32.
71. Carbone, M., Conrotto, D., Carrozzo, M., Broccoletti, R., Gandolfo, S., Scully, C. Topical corticosteroids in association with miconazole and chlorhexidine in the long-term management of atrophic-erosive oral lichen planus: A placebo-controlled and comparative study be tween clobetasol and fluocinonide. Oral Dis 1999, 5(1): 44-9.
72. Gonzalez-Moles, M.A., Morales, P., Rodriguez-Archilla, A., Isabel, I.R., Gonzalez-Moles, S. Treatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous solution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002, 93(3): 264-70.
73. Gilbertson, E.O, Spellman, M.C., Piacquadio, D.J., Mulford, M.I. Super potent topical corticosteroid use associated with adrenal suppression: Clinical considerations. J Am Acad Dermatol 1998, 38(2, Pt. 2): 318-21.
74. Ahn, S.K., Bak, H.N., Park, B.D. et al. Effects of a multilamellar emulsion on glucocorticoid-induced epidermal atrophy and barrier impairment. J Dermatol 2006, 33(2): 80-90.
75. du Vivier, A., Phillips, H., Hehir, M. Applications of glucocorticosteroids. The effects of twice-daily vs once-every-other-day applications on mouse epidermal cell DNA synthesis. Arch Dermatol 1982, 118(5): 305-8.
76. Woodbury, R., Kligman, A.M. The hairless mouse model for assaying the atrophogenicity of topical corticosteroids. Acta Derm Venereol 1992, 72(6): 403-6.
77. Sheu, H.M., Tai, C.L., Kuo, K.W., Yu, H.S., Chai, C.Y. Modulation of epidermal terminal differentiation in patients after long-term topical corticosteroids. J Dermatol 1991, 18(8): 454-64.
78. Sheu, H.M., Lee, J.Y., Kuo, K.W., Tsai, J.C. Permeability barrier abnormality of hairless mouse epidermis after topical corticosteroid: Characterization of stratum corneum lipids by ruthenium tetroxide staining and high-performance thin-layer chromatography. J Dermatol 1998, 25(5): 281-9.
79. Sheu, H.M., Lee, J.Y., Chai, C.Y., Kuo, K.W. Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroids. Br J Dermatol 1997, 136(6): 884-90.
80. Kao, J.S., Fluhr, J.W., Man, M.Q. et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: Inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 2003, 120(3): 456-64.
81. Prawer, S.E., Katz, H.I. Guidelines for using superpotent topical steroids. Am Fam Physician 1990, 41(5): 1531-8.